FIFARMA Regional Observatory

DATA AT THE SERVICE OF EVERYONE

Conozca el Health Innovation Outlook

El Health Innovation Outlook es uno de los estudios más completos que se ha realizado en América Latina, en el que se analizan e integran 55 indicadores, para comparar el desempeño de 11 países de la región en dos dimensiones: salud e innovación. En este estudio se destacan los avances de Argentina, Brasil, Chile, Colombia, Costa Rica, Ecuador, México, Panamá, Perú, República Dominicana y Uruguay y se identifican los retos y oportunidades para fortalecer sus sistemas de salud.

FIFARMA's Regional Observatory is a new data and analysis space for the sector's ecosystem to have the best information for decision making.

FIFARMA makes available to all interested parties this platform that streamlines access to open data from reliable sources, to provide a complete picture of health in the region in one place.

This is a space in constant evolution, at the service of national authorities, companies, unions, academics, and researchers.

EXPLORE THE DASHBOARDS

Health and Innovation Panorama

These data dashboards provide an agile visualization of the main health indicators in three dimensions: country profiles, health indicators and health innovation. This project is a FIFARMA and Innos collaboration for the promotion of transparency and evidence-based decision making.

ANALYSIS

Analysis and comments on the prospects and major challenges in health care

pexels-julie-viken-593451
What is the waiting time to access new cancer medications in Latin America?
pexels-photo-8736362
Impact of Vaccination on Economic and Social Well-Being
pexels-polina-tankilevitch-3735769
The new generation of vaccines for the uninitiated
Biogen 23 (2) (1)
Science and Society: The Path to an Inclusive Future

Observatory
of Health Regulatory Policy for Latin America

OPRES monitors and analyzes health policies and regulations in order to disseminate, explain and contribute to their improvement. A deliberation scenario in partnership with Innos.

An initiative of:

Latest publications

Understanding the dynamics of the health sector requires analysis, science and in-depth discussions. Learn about the latest reports published by FIFARMA and our strategic allies.

Position Paper

Patient W.A.I.T Indicator 2023 LATAM - Argentina

Though many molecules face reimbursement restrictions and uncertainty surrounding systemic changes exists, Argentina performs better than LATAM regional averages

Preview

Position Paper

Patient W.A.I.T Indicator 2023 LATAM - Brazil

Though many molecules face reimbursement restrictions and uncertainty surrounding systemic changes exists, Brazil performs better than LATAM regional averages

Preview

Position Paper

Patient W.A.I.T Indicator 2023 LATAM - Chile

Though many molecules face reimbursement restrictions and uncertainty surrounding systemic
changes exists, Colombia performs better than LATAM regional averages

Preview

Position Paper

Patient W.A.I.T Indicator 2023 LATAM - Colombia

Position Paper

Patient W.A.I.T Indicator 2023 LATAM - Costa Rica

Though many molecules face reimbursement restrictions and uncertainty surrounding systemic changes exists, Costa Rica performs lower than LATAM regional averages

Preview

Position Paper

Patient W.A.I.T Indicator 2023 LATAM - Ecuador

Though many molecules face reimbursement restrictions and uncertainty surrounding systemic changes exists, Ecuador performs lower than LATAM regional averages

Preview

Position Paper

Patient W.A.I.T Indicator 2023 LATAM - Peru

Though many molecules face reimbursement restrictions and uncertainty surrounding systemic changes exists, Peru performs lower than LATAM regional averages

Preview

Position Paper

Patient W.A.I.T Indicator 2023 LATAM - Mexico

Though many molecules face reimbursement restrictions and uncertainty surrounding systemic changes exists, Mexico performs better than LATAM regional averages

Preview

Position Paper

Office of Health Economics: según uninforme reciente, los programas devacunación para adultos representanbeneficios socioeconómicos de hasta 19 veces superiores a la inversión inicial

Un nuevo estudio demuestra que los programas de vacunación para adultos
representan un retorno de 19 veces su inversión inicial, si se valora todo el espectro de
beneficios.

Visualizar

Position Paper

Office of Health Economics: programas devacinação para adultos proporcionambenefícios socioeconômicos até 19 vezes doinvestimento inicial, segundo novo relatório

Estudo inovador mostra que os programas de imunização para adultos retornam até 19
vezes o investimento inicial, quando todo o espectro de benefícios é valorizado

Visualizar

Position Paper

Open letter from the biopharmaceutical industry to G20 Ministers in support of the advancement of the G20 Health Agenda

With ongoing negotiations in Geneva and less than six years left to achieve the Sustainable Development Goals (SDGs), the G20 forum serves as a key platform to promote constructive, coordinated, and collaborative solutions.

Preview

Position Paper

Carta abierta de la industria biofarmacéutica a los Ministros deSalud del G20 en apoyo al avance de la Agenda de Salud delG20

Con las negociaciones en curso en Ginebra y menos de seis años para lograr los Objetivos de Desarrollo Sostenible (ODS), el foro del G20 sirve como una plataforma clave para promover soluciones constructivas, coordinadas y colaborativas.
Visualizar

Position Paper

Carta aberta da indústria biofarmacêutica aos Ministros do G20 em apoio ao avanço da Agenda de Saúde do G20

Com as negociações em curso em Genebra e menos de seis anos restantes para alcançar os Objetivos de Desenvolvimento Sustentável (ODS), o fórum do G20 atua como uma plataforma fundamental para a promoção de soluções construtivas, coordenadas e colaborativas.

Visualizar

Position Paper

FIFARMA W.A.I.T Indicator 2023 - América Latina

Melhorar a disponibilidade de medicamentos inovadores na América Latina é uma prioridade para todas as partes interessadas no sistema de saúde, especialmente os legisladores, os fabricantes de produtos farmacêuticos e os pacientes.

Visualizar

Report

Patient WAIT Indicator 2023 Latin America (Final Report)

Improving the availability of innovative medicines in Latin America is a priority for all stakeholders in the healthcare system, especially policymakers, pharmaceutical manufacturers, and patients.

Preview

Explore the databases

Consult the data sources that FIFARMA and its partners make available to researchers, decision makers and authorities in the region.

Country
Aggregate national data on country health spending (2017)
Health
Aggregate national data on country health spending (2017)
Innovation
Aggregate national data on country health spending (2017)

Contact for researchers

If you have any questions, comments, or requests for information, please contact our team:

Email: info@fifarma.org

Health Innovation Outlook
Infografías